Xiao Gan

Abu Bakor Hayat Arnob, Xiangxue Wang, Yiping Jiao et al.

Medical image processing usually requires a model trained with carefully crafted datasets due to unique image characteristics and domain-specific challenges, especially in pathology. Primitive detection and segmentation in digitized tissue samples are essential for objective and automated diagnosis and prognosis of cancer. SAM (Segment Anything Model) has recently been developed to segment general objects from natural images with high accuracy, but it requires human prompts to generate masks. In this work, we present a novel approach that adapts pre-trained natural image encoders of SAM for detection-based region proposals. Regions proposed by a pre-trained encoder are sent to cascaded feature propagation layers for projection. Then, local semantic and global context is aggregated from multi-scale for bounding box localization and classification. Finally, the SAM decoder uses the identified bounding boxes as essential prompts to generate a comprehensive primitive segmentation map. The entire base framework, SAM, requires no additional training or fine-tuning but could produce an end-to-end result for two fundamental segmentation tasks in pathology. Our method compares with state-of-the-art models in F1 score for nuclei detection and binary/multiclass panoptic(bPQ/mPQ) and mask quality(dice) for segmentation quality on the PanNuke dataset while offering end-to-end efficiency. Our model also achieves remarkable Average Precision (+4.5%) on the secondary dataset (HuBMAP Kidney) compared to Faster RCNN. The code is publicly available at https://github.com/learner-codec/autoprom_sam.

Deisy Morselli Gysi, Ítalo Do Valle, Marinka Zitnik et al.

The current pandemic has highlighted the need for methodologies that can quickly and reliably prioritize clinically approved compounds for their potential effectiveness for SARS-CoV-2 infections. In the past decade, network medicine has developed and validated multiple predictive algorithms for drug repurposing, exploiting the sub-cellular network-based relationship between a drug's targets and disease genes. Here, we deployed algorithms relying on artificial intelligence, network diffusion, and network proximity, tasking each of them to rank 6,340 drugs for their expected efficacy against SARS-CoV-2. To test the predictions, we used as ground truth 918 drugs that had been experimentally screened in VeroE6 cells, and the list of drugs under clinical trial, that capture the medical community's assessment of drugs with potential COVID-19 efficacy. We find that while most algorithms offer predictive power for these ground truth data, no single method offers consistently reliable outcomes across all datasets and metrics. This prompted us to develop a multimodal approach that fuses the predictions of all algorithms, showing that a consensus among the different predictive methods consistently exceeds the performance of the best individual pipelines. We find that 76 of the 77 drugs that successfully reduced viral infection do not bind the proteins targeted by SARS-CoV-2, indicating that these drugs rely on network-based actions that cannot be identified using docking-based strategies. These advances offer a methodological pathway to identify repurposable drugs for future pathogens and neglected diseases underserved by the costs and extended timeline of de novo drug development.